Skip to content

Embecta Corp. EMBC Additional Paid-In Capital

Additional Paid-In Capital at other companies

Insulet logo
InsuletPODD
$1.28B+1.6%
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
$1.4B+5.0%
Medtronic logo
MedtronicMDT
$20.93B+0.4%
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.LFCR
$209.71M+1.5%
Mannkind logo
MannkindMNKD
$3.15B+0.8%
Beta Bionics, Inc. Common Stock logo
Beta Bionics, Inc. Common StockBBNX
$663.17M+3.8%

Other financials

Income statement

See full
Revenue$221.8M-14.4%
Gross profit$127.8M-22.1%
Operating income$35.0M-44.4%
Net income-$4.1M-117%
EPS (diluted)-$0.07-118%

Balance sheet

See full
Cash & equivalents$193.4M-8.9%
Total debt$1.4B-12.5%
Total equity-$626.1M+15.0%
Total assets$1.0B-8.1%

Cash flow

See full
Operating cash flow$31.1M-2.2%
CapEx$500.0K+400%
Free cash flow$30.6M-3.5%

Valuation

See full
Market cap$193.41M-64.3%
Enterprise value$1.37B-24.8%
P/E1.7×-4.8×
P/S0.2×-0.3×

Profitability

See full
Gross margin61.9%-1.6pp
Operating margin25.8%+9.7pp
Net margin10.7%+5.8pp
FCF margin19.6%+16.0pp

Returns & leverage

See full
Return on equity71.9%
Debt / equity
Current ratio2.5×0.0×

Where this comes from

Reported directly by Embecta Corp. in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Embecta Corp.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Embecta Corp.'s additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Embecta Corp.'s additional paid-in capital?
Embecta Corp. (EMBC) reported additional paid-in capital of $88M in Q1 2026.
How has Embecta Corp.'s additional paid-in capital changed year-over-year?
Embecta Corp.'s additional paid-in capital increased by 35.4% year-over-year, from $65M to $88M.
What is the long-term trend for Embecta Corp.'s additional paid-in capital?
Over 3 years (2022 to 2025), Embecta Corp.'s additional paid-in capital has grown at a 100.0% compound annual growth rate (CAGR), from $10M to $80M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.